SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE.X is trending as the community rallies around the token, emphasizing its strong community and potential in the AI companionship space. Some are discussing where to buy the crypto and encouraging others to hold, while also highlighting potential connections to other tokens like $UPDOG.X.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid rumors of a potential investment from Apple, sparking discussions about a possible resurgence and closer collaboration between the two tech giants. Community members are weighing in on the implications of such a deal, with some suggesting it could be a game-changer for Intel's turnaround efforts, while others express skepticism about the rumors. The stock's movement is also being attributed to broader government support and increased activity in the AI and chip sectors.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending after announcing positive results in its Huntington's disease gene therapy trial, driving significant excitement and a surge in stock price. The community is focused on the potential for FDA approval and the impact on patients, while also weighing the implications of a recently announced equity offering, including potential dilution and management's intentions.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Immuneering ($IMRX) is trending following positive trial data for their pancreatic cancer drug, with an impressive overall survival rate, which has the community buzzing about its potential. However, some investors express concerns about a potential offering impacting momentum, creating a debate between bulls focused on long-term potential and bears eyeing short-term opportunities. The community is closely monitoring upcoming announcements and potential partnerships that could further influence the stock's trajectory.

Eason Technology Ltd. engages in the provision of loan facilities to micro, small and medium size enterprises, and sole proprietors. It also offers microfinance lending services. The company was founded by Qi Ming Xu and Kang Kai Zeng on June 24, 2010 and is headquartered in Wuhan, China.

Eason Technology Ltd. - ADR

Eason Technology Ltd ADR

Eason Technology is trending as traders discuss its low float and potential for a significant price movement, drawing comparisons to other low-float stocks that have recently experienced substantial gains. The community is also monitoring the company's compliance with filings, anticipating a positive catalyst. Some investors believe the stock is being accumulated, setting the stage for a potential breakout.

Stitch Fix, Inc. engages in the provision of personalized shipments of apparel, shoes, and accessories. Its main sections are men's, kids, petite, maternity, and plus apparels. The company was founded by Katrina Lake and Erin Morrison Flynn in February 2011 and is headquartered in San Francisco, CA.

Stitch Fix Inc - Ordinary Shares - Class A

Stitch Fix Inc

Stitch Fix is trending due to its Q4 earnings report and FY25 guidance, sparking mixed reactions within the investment community. While the company beat EPS estimates, revenue guidance disappointed, leading to concerns about its turnaround plan and future growth, particularly with declining active clients. The community is actively discussing whether the company can achieve profitability and return to growth by the end of FY26, as projected by management.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz ($HTZ) is trending due to a recently announced partnership with Amazon to sell used vehicles through Amazon Autos, seen as a potential challenge to competitors like Carvana. The community is discussing the potential for a short squeeze, given the high short interest, and speculating on future partnerships with companies like Uber. Broader discussions include the company's turnaround efforts, potential for increased profitability, and influence from major investors like Bill Ackman.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as investors discuss its upcoming merger with quantum computing company Infleqtion and its potential in the quantum computing space. The community draws parallels to early-stage Tesla and Nvidia, emphasizing Infleqtion's existing contracts and revenue as a key differentiator from its peers. Some are also highlighting the potential of warrants (CCCXW) to outperform.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul C. Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

PINS is trending amid discussions around potential competitor threats from Google and Instagram, and anticipation for the company's upcoming presentation and earnings call. The community is debating whether the recent price action represents a buying opportunity or a sign of deeper issues, pointing to revenue growth and MAU increases as positives, while also acknowledging volatility and possible sector weakness. Some traders are eyeing near-term price movements with options strategies, while others are holding for a longer-term potential buyout.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: North America Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, Rod and Refining, Atlantic Copper Smelting and Refining, and Corporate and Other. The North America Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The Rod and Refining segment consists of copper conversion facilities located in North America and includes a refinery and rod mills. The Atlantic Copper Smelting and Refining segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan ($FCX) is trending due to a mine incident in Indonesia impacting copper and gold production forecasts, leading to market overreaction and a stock decline. The community is debating the severity of the production halt and its effect on the company's financials, while some see this as a buying opportunity due to strong copper prices and long-term demand. Discussions also include potential lawsuits and concerns about management's handling of the situation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TNF Pharmaceuticals, Inc. (TNFA) announced on Wednesday that it has changed its corporate name to Q/C Technologies and will begin trading under a new ticker on the Nasdaq Capital Market starting Thursday.TNF Pharmaceuticals stated that no action is required from current shareholders regarding the name change. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tnfpharma.com/news-events/press-releases/detail/81/tnf-pharmaceuticals-announces-name-change-to-qc">noted</a> that the new name represents the company’s recent strategic pivot into quantum-class computing. The company has exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system for application in the cryptocurrency vertical.LPUs can reduce energy consumption by up to 90% while outperforming traditional GPUs and quantum computing in both speed and efficiency, the company said. Lighsolver’s architecture is further designed to improve security for blockchain operations and is expected to position the company at the forefront of innovation in blockchain infrastructure, the company said.Following the announcement, <a href="https://stocktwits.com/symbol/TNFA">TNFA shares</a> surged by about 101% by the afternoon of Wednesday. On Stocktwits, retail sentiment around TNFA jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels. The stock will begin trading under the new ticker symbol QCLS starting Thursday, September 25.The company added that it also continues to evaluate strategic options for its therapeutic programs, Isomyosamine and Supera-CBD. While Isomyosamine has potential for the treatment of chronic inflammation, Supera-CBD holds potential in managing addiction. The company is looking to realize maximum value from these assets as it undertakes the pivot into computing and blockchain infrastructure.TNFA stock is down by 94% this year.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TNF Pharmaceuticals Stock More Than Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing

The company holds exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system designed for use in the cryptocurrency sector.

TNF Pharmaceuticals Stock Nearly Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing

Equity

The company holds exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system designed for use in the cryptocurrency sector.


Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.GlucoTrack (GCTK)GlucoTrack posted the highest increase in retail chatter, with message volume surging 3,700% over the past seven days. As of late Sunday, sentiment remained ‘bullish’ among retail traders.On July 8, the company announced the repurchase of over 90% of its Series A Warrants, funded with cash on hand.&nbsp;The move followed last month’s disclosure of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glucotrack-announces-positive-results-from-implantable-blood-glucose-monitor-study/chmJoJwRREo">positive results</a> from its first-in-human clinical study of its continuous blood glucose monitor (CBGM).The implantable device demonstrated 99% data capture, strong accuracy, and no serious adverse events. Designed for a three-year lifespan, the CBGM measures blood glucose directly, not interstitial fluid, and requires no on-body wearable.&nbsp;A long-term feasibility study is expected to launch in Q3 2025.<a href="https://stocktwits.com/symbol/GCTK">GCTK’s stock</a> has declined 98.5% so far in 2025.Sarepta Therapeutics (SRPT)Sarepta saw a 1,991% increase in message volume over the past week, with sentiment remaining ‘extremely bullish’ as of late Sunday, despite mounting regulatory concerns.On July 19, shares plunged over 26% in midday trading after FDA Commissioner Marty Makary said the agency is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-taking-a-hard-look-to-at-whether-sarepta-gene-therapy-elevidys-should-remain-on-the-market/ch8kDByR5qt">“taking a hard look”</a> at whether Sarepta’s gene therapy, Elevidys, should stay on the market.The company disclosed a third patient death on July 18, involving a 51-year-old participant in a limb-girdle muscular dystrophy trial using a similar viral vector to Elevidys. Two earlier deaths were already under FDA investigation. Reuters reported the agency plans to request a voluntary halt to Elevidys' shipments.Amid the fallout,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">analysts criticized Sarepta</a> for not disclosing the fatality earlier, particularly during a recent business update where it announced a 500-job layoff and $400 million in cost cuts.&nbsp;The company has since paused shipments to non-ambulatory patients and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-surges-after-hours-as-it-slashes-500-jobs-amid-fda-black-box-warning-for-gene-therapy-retail-eyes-rebound/ch8KR0HR5oM">agreed to a black box warning</a> for Elevidys, citing the risk of acute liver failure.<a href="https://stocktwits.com/symbol/SRPT">SRPT’s stock</a> has declined 88.7% so far in 2025.TNF Pharmaceuticals (TNFA)TNF Pharma recorded a 1,900% rise in message volume over the past seven days on Stocktwits, with sentiment labeled ‘extremely bullish’ as of late Sunday.Although there was no specific news catalyst driving the buzz last week, the momentum has been strong since last month when TNFA announced a Compassionate Use collaboration with the DADA2 Foundation to study isomyosamine as a treatment for DADA2, a rare pediatric autoinflammatory disorder.In April,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tnf-pharmaceuticals-to-use-ai-to-recruit-patients/chQSz8ARbXp">TNFA partnered with Renova Health</a> to apply AI and machine learning to optimize patient recruitment. The company is analyzing data from 30,000 patients to identify high-risk cohorts, particularly for interventions related to inflammation and side effects of GLP-1 therapy.TNFA’s pipeline includes two drug platforms: isomyosamine, which regulates inflammatory pathways, and Supera-CBD, which targets chronic pain, addiction, and epilepsy.<a href="https://stocktwits.com/symbol/TNFA">TNFA’s stock</a> has declined 92.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-stealthily-hiked-prices-on-everyday-essentials-as-trump-tariffs-bit-report/ch8qvlTR5Ae">Amazon Stealthily Hiked Prices On Everyday Essentials As Trump Tariffs Bit: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GlucoTrack (GCTK), Sarepta Therapeutics (SRPT), and TNF Pharmaceuticals (TNFA) recorded the highest increases in message volume among healthcare names on Stocktwits. (Photo credit: Getty Images)

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Shares of TNF Pharmaceuticals, Inc. (TNFA) traded nearly 5% higher on Tuesday afternoon after it announced a partnership with Renova Health for the application of AI and machine learning technologies to recruit patients for its isomyosamine drug development.Isomyosamine is a drug platform based on a clinical stage small molecule that is being developed to treat diseases and disorders marked by acute or chronic inflammation.The clinical-stage pharmaceutical company stated that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.The company stated that the TNF-Renova partnership is analyzing data from 30,000 patients to identify high-risk patients.Renova CEO David Jacobs said that its technology transcends traditional big data analytics by creating highly specific patient personas.“Our platform uncovers the nuanced impact of individual physician practices—such as varying diagnosis codes for GLP-1 prescriptions, like BMI versus diabetes—which can significantly influence cohort selection and study outcomes,” he said.Isomyosamine is the first of two therapeutic platforms being developed by TNF Pharmaceuticals. While Isomyosamine is being developed to regulate inflammation, the company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.On Stocktwits, retail sentiment around TNF remained unmoved in the ‘bearish’ territory over the past 24 hours while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1292/304;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_22_at_2_09_23_PM_png_87841bd4ef.webp" alt="TNFA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on April 22, 2025 | Source: Stocktwits" width="1292" height="304"><figcaption>TNFA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on April 22, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/TNFA">TNFA stock</a> is down by over 84% so far this year and by over 93% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jd-vance-says-significant-progress-made-with-india-on-trade-deal/chQSwMaRbXn">Vice President JD Vance Calls Indian PM Narendra Modi A ‘Tough Negotiator’ As US, India Negotiate Bilateral Trade Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish

The company said that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment.

The company said that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNF or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today...

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNFA or the Company), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions...

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNFA or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and...

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNF Pharmaceuticals Inc.

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

Costco Wholesale Corp

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

TNFA
TNF Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNFA News

TNFA TNF Pharmaceuticals Inc.